**Protocol for the Examination of Specimens From Patients With Carcinoma of the Small Intestine**

**Version:** 4.2.0.0

**Protocol Posting Date:** June 2021

**CAP Laboratory Accreditation Program Protocol Required Use Date:** March 2022

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

**For accreditation purposes, this protocol should be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Resection | Includes specimens designated segmental resection, pancreaticoduodenectomy (Whipple resection), ileocolic resection |
| **Tumor Type** | **Description** |
| Carcinoma | Including carcinomas arising in the duodenum, jejunum, and ileum |

**This protocol is NOT required for accreditation purposes for the following:**

|  |
| --- |
| **Procedure** |
| Biopsy |
| Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy) |
| Recurrent tumor |
| Cytologic specimens |

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| Carcinoma of the ampulla (consider Ampullary Carcinoma protocol) |
| Well-differentiated neuroendocrine tumor of the duodenum (consider the Duodenal and Ampullary NET protocol) |
| Well-differentiated neuroendocrine tumor of the jejunum and ileum (consider the Jejunal and Ilial NET protocol) |
| Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols) |
| Gastrointestinal stromal tumor (GIST) (consider the GIST protocol) |
| Non-GIST sarcoma (consider the Soft Tissue protocol) |

**Authors**

Lawrence J. Burgart, MD\*; William V. Chopp, MD\*; Dhanpat Jain, MD\*.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
\* Denotes primary author.

**Accreditation Requirements**

**This** protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

* Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
* Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
* Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

**Synoptic Reporting**

All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

* Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
* The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
* Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
	+ Anatomic site or specimen, laterality, and procedure
	+ Pathologic Stage Classification (pTNM) elements
	+ Negative margins, as long as all negative margins are specifically enumerated where applicable
* The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

**Summary of Changes**

**v 4.2.0.0**

* General Reformatting
* Revised Margins Section
* Revised Lymph Nodes Section
* Added Distant Metastasis Section
* Removed pTX and pNX Staging Classification

**Reporting Template**

**Protocol Posting Date: June 2021**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (SMALL INTESTINE)**

**Standard(s)**: AJCC-UICC 8

**SPECIMEN**

**Procedure**

\_\_\_ Segmental resection

\_\_\_ Ileocolic resection

\_\_\_ Pancreaticoduodenectomy (Whipple resection)

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**TUMOR**

**Tumor Site (Note** [**A**](#1875)**)**

\_\_\_ Duodenum: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Jejunum: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Ileum: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Small intestine, not otherwise specified: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Histologic Type (Note** [**B**](#1876)**)**

\_\_\_ Adenocarcinoma (not otherwise characterized)

\_\_\_ Mucinous adenocarcinoma (greater than 50% mucinous)

\_\_\_ Poorly cohesive cell carcinoma with or without signet-ring cells

\_\_\_ Medullary carcinoma

\_\_\_ Adenosquamous carcinoma

\_\_\_ Squamous cell carcinoma

\_\_\_ Large cell neuroendocrine carcinoma

\_\_\_ Small cell neuroendocrine carcinoma

*# Select this option only if large cell or small cell cannot be determined.*

\_\_\_ Neuroendocrine carcinoma (poorly differentiated)#

\_\_\_ Mixed adenocarcinoma-neuroendocrine carcinoma

\_\_\_ Undifferentiated carcinoma

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (Note** [**C**](#1877)**)**

\_\_\_ G1, well differentiated

\_\_\_ G2, moderately differentiated

\_\_\_ G3, poorly differentiated

\_\_\_ G4, undifferentiated

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ GX, cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**Tumor Size**

\_\_\_ Greatest dimension in Centimeters (cm): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

**+Additional Dimension in Centimeters (cm): \_\_\_\_ x \_\_\_\_ cm**

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Extent**

\_\_\_ High-grade dysplasia / carcinoma in situ

\_\_\_ Invades lamina propria

\_\_\_ Invades submucosa

\_\_\_ Invades muscularis propria

\_\_\_ Invades through muscularis propria into subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration

\_\_\_ Perforates visceral peritoneum

\_\_\_ Directly invades other organ(s) or structure(s)

\_\_\_ Other loops of small intestine

\_\_\_ Mesentery of adjacent loops of bowel

\_\_\_ Abdominal wall (by way of serosa)

*For Duodenum Only*

\_\_\_ Pancreas

\_\_\_ Bile duct

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ No evidence of primary tumor

**Macroscopic Tumor Perforation**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Lymphovascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**MARGINS (Note** [**D**](#1878)**)**

**Margin Status for Invasive Carcinoma**

\_\_\_ All margins negative for invasive carcinoma

**+Closest Margin(s) to Invasive Carcinoma (select all that apply)**

\_\_\_ Proximal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Distal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Radial or mesenteric: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Uncinate (retroperitoneal / superior mesenteric artery): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Bile duct: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Pancreatic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Distance from Invasive Carcinoma to Closest Margin**

*Specify in Centimeters (cm)*

\_\_\_ Exact distance in cm: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Greater than 1 cm

*Specify in Millimeters (mm)*

\_\_\_ Exact distance in mm: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Greater than 10 mm

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Invasive carcinoma present at margin

**Margin(s) Involved by Invasive Carcinoma (select all that apply)**

\_\_\_ Proximal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Distal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Radial or mesenteric (tumor present 0-1 mm from margin): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Uncinate (retroperitoneal / superior mesenteric artery) (tumor present 0-1 mm from margin): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Bile duct: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Pancreatic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**Margin Status for Dysplasia (select all that apply)**

\_\_\_ All margins negative for carcinoma in situ (high-grade dysplasia) / adenoma

\_\_\_ Carcinoma in situ (high-grade dysplasia) present at margin

**Margin(s) Involved by Carcinoma in Situ (select all that apply)**

\_\_\_ Proximal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Distal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Adenoma present at margin

**Margin(s) Involved by Adenoma (select all that apply)**

\_\_\_ Proximal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Distal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**+Margin Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**REGIONAL LYMPH NODES**

**Regional Lymph Node Status**

\_\_\_ Not applicable (no regional lymph nodes submitted or found)

\_\_\_ Regional lymph nodes present

\_\_\_ All regional lymph nodes negative for tumor

\_\_\_ Tumor present in regional lymph node(s)

**Number of Lymph Nodes with Tumor**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Number of Lymph Nodes Examined**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Regional Lymph Node Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**DISTANT METASTASIS**

**Distant Site(s) Involved, if applicable (select all that apply)**

\_\_\_ Not applicable

\_\_\_ Non-regional lymph node(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Liver: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition) (Note** [**E**](#1879)**)**

*Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.*

**TNM Descriptors (select all that apply)**

\_\_\_ Not applicable

\_\_\_ m (multiple primary tumors)

\_\_\_ r (recurrent)

\_\_\_ y (post-treatment)

**pT Category**

\_\_\_ pT not assigned (cannot be determined based on available pathological information)

\_\_\_ pT0: No evidence of primary tumor

\_\_\_ pTis: High-grade dysplasia / carcinoma in situ

*pT1: Tumor invades the lamina propria or submucosa*

\_\_\_ pT1a: Tumor invades the lamina propria

\_\_\_ pT1b: Tumor invades the submucosa

\_\_\_ pT1 (subcategory cannot be determined)

\_\_\_ pT2: Tumor invades the muscularis propria

*# For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas.*

\_\_\_ pT3: Tumor invades through the muscularis propria into the subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration#

\_\_\_ pT4: Tumor perforates the visceral peritoneum or directly invades other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct)

**pN Category**

\_\_\_ pN not assigned (no nodes submitted or found)

\_\_\_ pN not assigned (cannot be determined based on available pathological information)

\_\_\_ pN0: No regional lymph node metastasis

\_\_\_ pN1: Metastasis in one or two regional lymph nodes

\_\_\_ pN2: Metastasis in three or more regional lymph nodes

**pM Category (required only if confirmed pathologically)**

\_\_\_ Not applicable - pM cannot be determined from the submitted specimen(s)

\_\_\_ pM1: Distant metastasis

**ADDITIONAL FINDINGS (Note** [**F**](#1880)**)**

**+Additional Findings (select all that apply)**

\_\_\_ None identified

\_\_\_ Adenoma(s)

\_\_\_ Crohn disease

\_\_\_ Celiac disease

\_\_\_ Other polyp(s) (specify type[s]): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**SPECIAL STUDIES (Note** [**G**](#1881)**)**

*For reporting molecular testing and immunohistochemistry for mismatch repair proteins, and for other cancer biomarker testing results, the CAP Colorectal Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.*

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. Tumor Site**

The majority of small intestinal carcinomas arise in the duodenum (64%),[1](#7008) most commonly around the ampulla of Vater (Figure 1). Approximately 20% arise in the jejunum and 15% in the ileum. Duodenal location has been implicated as a risk factor for poorer outcome.[2](#7009)



**Figure 1.** Anatomical sites of the small intestine. From: Greene FL et al.[3](#7010) Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com/).

References

1. Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999;86:2693-2706
2. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518-526.
3. Greene FL, Compton, CC, Fritz AG, et al, eds. AJCC Cancer Staging Atlas. New York: Springer; 2006.

**B. Histologic Type**

The most common tumor types arising in the small intestine are adenocarcinomas (24% to 44%), well -differentiated neuroendocrine tumors (20% to 42%), gastrointestinal stromal tumors (7% to 9%), and lymphoma (12% to 27%).[1](#7011)  Separate CAP cancer protocols apply to well-differentiated neuroendocrine tumors, gastrointestinal stromal tumors, and lymphomas.

For carcinomas of the small intestine, the protocol recommends the histologic classification published by the World Health Organization (WHO).[2](#7012)

References

1. Zeh HJ. Cancer of the small intestine. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
2. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1).

**C. Histologic Grade**

A histologic grading system for adenocarcinomas based on the extent of glandular formation in the tumor is recommended, as shown below.

Grade X Grade cannot be assessed

Grade 1 Well differentiated (more than 95% of tumor composed of glands)

Grade 2 Moderately differentiated (50% to 95% of tumor composed of glands)

Grade 3 Poorly differentiated (less than 50% of tumor composed of glands)

Grade 4 is reserved for small cell neuroendocrine carcinoma and undifferentiated carcinoma (WHO classification).

Most small bowel carcinomas are moderately differentiated, followed by poorly differentiated; a minority are well differentiated. Grade does not appear to be a strong predictor of outcome.[1,](#7013)[2](#7014)

References

1. Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999;86:2693-2706.
2. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518-526.

**D. Margins**

For segmental small bowel and ileocolic resections, margins include the proximal, distal, and mesenteric margins of resection. For all small bowel segments, except the duodenum, the mesenteric resection margin is the only pertinent radial margin (Figure 2). For pancreaticoduodenectomy specimens of carcinomas of the duodenum, the proximal margin of stomach or duodenum (pylorus-sparing Whipple resection) and the distal resection margin of duodenum are more biologically relevant than in pancreaticoduodenectomy procedures performed for pancreatic carcinoma and should always be sampled. The nonperitonealized surface of the uncinate process (uncinate margin) constitutes the inferior-posterior retroperitoneal margin of pancreaticoduodenectomy specimens. A perpendicular section through the closest approach of tumor to the margin should be taken. This margin has also been referred to as retroperitoneal margin and superior mesenteric artery margin. Complete en face sections through the pancreatic resection margin and the common bile duct margin should also be taken.



**Figure 2.** A. Mesenteric margin in small intestine completely encased by peritoneum (dotted line). B. Circumferential margin (dotted line) in portion of proximal duodenum incompletely encased by peritoneum. C. Circumferential margin (dotted line) in retroperitoneal portion of duodenum completely unencased by peritoneum.

**E. Pathologic Stage Classification**

Surgical resection is the most effective therapy for small intestinal carcinoma,[1](#7016) and the best estimation of prognosis is related to the anatomic extent (stage) of disease at the time of resection.

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC)[2](#7017) and the International Union Against Cancer (UICC)[3](#7018) but does not preclude the use of other staging systems.

According to AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically infeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or after initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor before multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval and is identified by the “r” prefix: rTNM.

T Category Considerations

pTis. For small intestinal carcinomas, 'carcinoma in situ' (pTis) as a staging term includes cancer cells confined within the glandular basement membrane (high-grade dysplasia). The term “carcinoma in situ” is not widely applied to glandular neoplastic lesions in the gastrointestinal tract but is retained for tumor registry reporting purposes as specified by law in many states. Tumor invasive into the mucosal lamina propria, up to but not through the muscularis mucosae (intramucosal carcinoma), is classified as pT1a. This designation differs from that for colon, in which tumor extension into the lamina propria is regarded as in situ carcinoma, because of the rich lymphatic network in small intestinal mucosa. Tumor extension through the muscularis mucosae into the submucosa is classified as T1b (Figure 3). T2 tumors invade the muscularis propria (Figure 4), and T3 tumors invade subserosal tissues without extension to the peritoneal (serosal) surface or invasion of adjacent organs (Figure 5).

 

**Figure 3.** T1a (left side) with tumor invasion of the lamina propria; T1b (right side) with tumor invasion of the submucosa. From: Greene FL et al.[4](#7019) Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).



**Figure 4.** T2 is defined as tumor invading the muscularis propria. From: Greene FL et al.[4](#7019) Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).



**Figure 5.** T3 tumors invade through the muscularis propria into subserosal adipose tissue; T4 tumor perforates the peritoneal (serosal) surface. From: Greene FL et al.4 Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

pT4 includes tumors perforating the visceral peritoneum (Figure 5) or directly invading other organs or structures, including invasion of other segments of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of the serosa (Figure 6). In such a case, both an adjacent organ and the visceral peritoneum are penetrated by tumor. Intramural extension of tumor from the terminal ileum into the cecum does not affect the pT classification.[4](#7019)For duodenal tumors, invasion of the pancreas and the bile duct is considered as T4 (Figure 7).



**Figure 6.** T4 tumor directly invadesother organs or structures, including other loops of small intestine. From: Greene FL et al.[4](#7019) Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).



**Figure 7.**T4 tumor of the duodenum invadesthe pancreas. From: Greene FL et al.[4](#7019) Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).

Tumor that is adherent to other organs or structures macroscopically is classified as cT4. However, if no tumor is found within the adhesion and no perforation of the visceral peritoneum identified microscopically, the tumor should be assigned pT3.

Tumor in veins or lymphatics does not affect the pT classification.

There are no T4a and T4b subcategories for small intestinal carcinomas in the AJCC 8th edition.

N Category Considerations

The regional lymph nodes for the anatomical subsites of the small intestine are as follows:[2](#7017)

Duodenum: retropancreatic, hepatic artery, inferior pancreaticoduodenal, and superior mesenteric

Ileum and jejunum: cecal (terminal ileum only), ileocolic (terminal ileum only), superior mesenteric, mesenteric, NOS

Submission of lymph nodes for microscopic examination. All grossly negative or equivocal lymph nodes are to be submitted entirely. Grossly positive lymph nodes may be partially submitted for microscopic confirmation of metastasis.

The minimum number of lymph nodes that predicts regional node negativity has not been defined for small intestinal cancers. The pathology report should clearly state the total number of lymph nodes examined and the total number involved by metastases. Data are insufficient to recommend routine use of tissue levels or special/ancillary techniques to detect micrometastases or isolated tumor cells.

Nonregional lymph nodes. For microscopic examination of lymph nodes in large resection specimens, lymph nodes must be designated as regional versus nonregional, according to the anatomic location of the tumor. Metastasis to nonregional lymph nodes is classified as distant metastasis and designated as M1. Nonregional lymph nodes include celiac and para-aortic nodes.

Additional Descriptors

Lymphovascular Invasion

Lymphovascular invasion (LVI) indicates whether microscopic lymphatic and/or vascular invasion is identified in the pathology report. LVI includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

References

1. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518-526.
2. Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
3. Brierley JD, Gospodarowicz MK, Wittekind C, et al, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford, UK: Wiley; 2016.
4. Greene FL, Compton, CC, Fritz AG, et al, eds. AJCC Cancer Staging Atlas. New York: Springer; 2006.

**F. Additional Findings**

Conditions that predispose to small bowel malignancy include Crohn disease, celiac disease, inherited polyposis syndromes (including familial adenomatous polyposis and Peutz-Jeghers syndrome), and Lynch syndrome.

Small intestinal adenocarcinomas in Crohn disease arise in the setting of long-standing ileal inflammation; cumulative risk increases after 10 years of Crohn disease, although absolute risk (2.2% at 25 years) remains low.[1](#7020) Signet-ring cell carcinomas appear to be more common in Crohn disease than as de novo small intestinal carcinomas.[2](#7021)

Small intestinal carcinomas are more frequent in polyposis syndromes, most notably in familial adenomatous polyposis, in which approximately 2.3% of patients developed a duodenal adenocarcinoma;[3](#7022) most tumors in these patients develop in the periampullary region, and the duodenum may be carpeted with adenomas. Peutz-Jeghers syndrome[4](#7023) is also associated with higher risk of small intestinal carcinoma.

Patients with Lynch syndrome have an approximately 4% lifetime risk of developing a small bowel carcinoma; this risk exceeds that of the normal population by 100-fold. Duodenum and jejunum are the most common primary sites, and the small bowel is the first site of cancer in approximately one-fourth of Lynch syndrome patients who develop small bowel tumors.[5](#7024) Histopathologic features of Lynch syndrome-associated small intestinal carcinomas are similar to those of colorectal carcinomas arising in this setting; mucinous carcinomas are overrepresented, and tumors often show a high number of intratumoral lymphocytes and Crohn-like lymphoid reaction.[6](#7025)

References

1. Friedman S. Cancer in Crohn's disease. [Review] [102 refs]. Gastroenterol Clin North Am. 2006;35:621-639.
2. Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11:828-832
3. Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1:1149-1151.
4. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209-3215
5. Rodriguez-Bigas MA, Vasen HF, Lynch HT, et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC. Cancer. 1998;83:240-244.
6. Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology. 2005;128:590-599.

**G. Ancillary Procedures**

Testing for defects in mismatch repair in small intestinal carcinomas is important for detection of Lynch syndrome. Examination of the tissue for defective DNA mismatch repair should be considered in small intestinal carcinomas regardless of the patient’s age,[1](#7026) if other predisposing conditions such as familial adenomatous polyposis coli are absent. In addition, emerging data suggest that the frequency of microsatellite instability in small intestinal carcinomas is approximately equal to that of colon cancer[2](#7027) and may be associated with better survival.[3](#7028) However, this latter indication for testing is not clearly established and has not been accepted as standard of care.

References

1. Umar A, Boland R, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst. 2004;96:261-268.
2. Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer. 2003;97:1551-1557.
3. Brueckl WM, Heinze E, Milsmann C, et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Letters. 2004;203:181-190.